CBAY — CymaBay Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $3.73bn
- $3.44bn
- $31.07m
Annual cashflow statement for CymaBay Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -103 | -51 | -90 | -106 | -105 |
| Depreciation | |||||
| Non-Cash Items | 8.23 | 7.22 | 13.5 | 23.6 | 26.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.91 | -1.59 | 6.35 | -2.34 | 5.63 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -97.9 | -44.7 | -69.4 | -84.1 | -72.5 |
| Capital Expenditures | -0.315 | -0.021 | -0.087 | -0.148 | -0.445 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -34 | 48 | 48.7 | -45.8 | -86.1 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -34.3 | 48 | 48.6 | -46 | -86.6 |
| Financing Cash Flow Items | 108 | 0 | — | -0.459 | 335 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 108 | 0.092 | 118 | 24.6 | 346 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -24.1 | 3.32 | 97.6 | -106 | 187 |